HotSpot Therapeutics, Inc. Email Format
Biotechnology ResearchMassachusetts, United States51-200 Employees
HotSpot Therapeutics, Inc. is a Boston-area biotechnology company pursuing allosteric therapies that regulate protein function by engaging regulatory hotspots away from active sites. This approach aims to deliver highly selective medicines with strong in vivo activity and favorable drug-like properties to address diseases with limited or no established treatments. In 2026 the company launched an interferon regulatory factor 5 (IRF5) program and presented preclinical data at the European Lupus Meeting. The company has previously collaborated with AbbVie on IRF5 inhibitors for autoimmune diseases. Based in Boston, Massachusetts, HotSpot is a mid-sized organization focused on translating regulatory hotspot biology into oral therapies.